SG11202112499VA - Treatment of heart disease by disruption of the anchoring of pp2a - Google Patents

Treatment of heart disease by disruption of the anchoring of pp2a

Info

Publication number
SG11202112499VA
SG11202112499VA SG11202112499VA SG11202112499VA SG11202112499VA SG 11202112499V A SG11202112499V A SG 11202112499VA SG 11202112499V A SG11202112499V A SG 11202112499VA SG 11202112499V A SG11202112499V A SG 11202112499VA SG 11202112499V A SG11202112499V A SG 11202112499VA
Authority
SG
Singapore
Prior art keywords
pp2a
disruption
anchoring
treatment
heart disease
Prior art date
Application number
SG11202112499VA
Inventor
Michael S Kapiloff
Jinliang Li
Original Assignee
Univ Miami
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami, Univ Leland Stanford Junior filed Critical Univ Miami
Publication of SG11202112499VA publication Critical patent/SG11202112499VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1719—Muscle proteins, e.g. myosin or actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11202112499VA 2019-05-15 2020-03-13 Treatment of heart disease by disruption of the anchoring of pp2a SG11202112499VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962848156P 2019-05-15 2019-05-15
PCT/US2020/022721 WO2020231503A1 (en) 2019-05-15 2020-03-13 Treatment of heart disease by disruption of the anchoring of pp2a

Publications (1)

Publication Number Publication Date
SG11202112499VA true SG11202112499VA (en) 2021-12-30

Family

ID=71996042

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112499VA SG11202112499VA (en) 2019-05-15 2020-03-13 Treatment of heart disease by disruption of the anchoring of pp2a

Country Status (7)

Country Link
US (2) US11938198B2 (en)
EP (1) EP3969032A1 (en)
JP (1) JP2022532763A (en)
AU (1) AU2020276156A1 (en)
CA (1) CA3139974A1 (en)
SG (1) SG11202112499VA (en)
WO (1) WO2020231503A1 (en)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489125B1 (en) 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030194704A1 (en) 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
PT2284266E (en) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Sirna targeting tp53
MXPA05012619A (en) 2003-05-21 2006-02-08 Univ Texas Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure.
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US10029386B2 (en) 2009-08-26 2018-07-24 Robert Bosch Tool Corporation Table saw with positive locking mechanism
EP2635300A4 (en) 2010-11-03 2014-04-02 Ibc Pharmaceuticals Inc Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
US20130136729A1 (en) 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
US9132174B2 (en) 2013-03-15 2015-09-15 Anchored Rsk3 Inhibitors, Llc Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
US10109346B2 (en) 2014-07-30 2018-10-23 Hewlett Packard Enterprise Development Lp Apparatus having a memory cell and a shunt device
EP3658157B1 (en) 2017-07-06 2023-07-26 Michael S. Kapiloff Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)

Also Published As

Publication number Publication date
CA3139974A1 (en) 2020-11-19
WO2020231503A1 (en) 2020-11-19
EP3969032A1 (en) 2022-03-23
US20240165268A1 (en) 2024-05-23
WO2020231503A9 (en) 2021-01-07
US20220008560A2 (en) 2022-01-13
US20200360536A1 (en) 2020-11-19
JP2022532763A (en) 2022-07-19
US11938198B2 (en) 2024-03-26
AU2020276156A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
IL276383B1 (en) Treatment of ophthalmologic diseases
EP3261671A4 (en) Combination therapy for treatment of coronary artery disease
IL287904A (en) Combination treatment of arthritic disease
SG11202010585WA (en) New treatment of interstitial lung diseases
IL281244A (en) Combination therapy for the treatment of liver disease
EP3796928A4 (en) Treatment of gaucher disease
GB202015959D0 (en) Treatment of diseases involving NAD
IL283263A (en) Treatment of skin disorders based on electrolysed water
EP3658157A4 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
GB201805100D0 (en) Treatment of sarcopenic diseases
EP3592377A4 (en) Dosage forms of tissue kallikrein 1
IL291626A (en) Treatment of celiac disease
SG11202112499VA (en) Treatment of heart disease by disruption of the anchoring of pp2a
IL280638A (en) Fat tissue treatment
EP3846843A4 (en) Compositions and methods for the treatment of heart disease
GB201604359D0 (en) Treatment of tissue disorders
GB201909732D0 (en) Cardiac therapeutic
IL280243A (en) 17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure
GB201908180D0 (en) Therapy for heart disorders
GB201911728D0 (en) Bacterial composistions for the treatment of disease
CA194090S (en) Patient monitor
GB201909438D0 (en) Treatment of diseases
GB201904012D0 (en) Regulation of blood glucoe via human microbioma
GB201811911D0 (en) Treatment of disease